ADVOCATE. CONNECT. INNOVATE.

Category Archives: CLSA Home

Federal Update: Tax Reform & Impact on the Life Sciences Sector

Congress is currently advancing legislation in both chambers to significantly overhaul the U.S. tax code. Historically, CLSA has focused our tax-related advocacy efforts around: (1) calling for an update and making permanent of the R&D Tax Credit, (2) protecting the Orphan Drug Tax Credit (ODTC), and (3) opposing the creation of and later calling for a repeal of the medical device tax.

2018 Report from California Life Sciences Association, PwC Details New Peaks for Life Sciences Industry in California

California Life Sciences Association (CLSA) and PwC US newly released annual California Life Sciences Industry Report, provides a snapshot of the largest life sciences cluster in the world. The 2018 report shows that California continues to outpace other states in life science-related economic growth, including venture funding, National Institutes of Health (NIH) funding, digital health venture funding, and is producing nearly 300,000 jobs and shepherding more than a thousand new therapies through the pipeline.

NIH Partners with 9 CLSA Member Biopharma Companies to Accelerate Cancer Therapy Innovation

On Oct. 12, the National Institutes of Health (NIH) announced a new partnership with 11 biopharmaceutical companies aimed at accelerating innovation in new cancer immunotherapy therapies. Nine of the 11 companies are CLSA members: AbbVie; Amgen; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene Corporation; Genentech, a member of the Roche Group; Gilead Sciences; Janssen Pharmaceutical Companies of Johnson & Johnson; and Pfizer, Inc.